Claims for Patent: 7,189,827

Summary for Patent: 7,189,827

Title:	Modified peptides as therapeutic agents
Abstract:	The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.
Inventor(s):	Feige; Ulrich (Newbury Park, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	10/632,388
Patent Claims:	1. A composition of matter of the formula (X.sup.1).sub.a--F.sup.1--(X.sup.2).sub.b and multimers thereof, wherein: F.sup.1 is an Fc domain; X.sup.1 and X.sup.2 are each independently selected from -(L.sup.1).sub.c-P.sup.1, -(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2, -(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2-(L.sup.3).sub.e-P.sup.3, and -(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2-(L.sup.3).sub.e-P.su- p.3-(L.sup.4).sub.f-P.sup.4 P.sup.1, P.sup.2, P.sup.3, and P.sup.4 are each independently randomized TPO-mimetic peptide sequences; L.sup.1, L.sup.2, L.sup.3, and L.sup.4 are each independently linkers; and a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1 and wherein "peptide" refers to molecules 2 to 40 amino acid and wherein neither X.sup.1 nor X.sup.2 is a native protein. 2. The composition of matter of claim 1 of the formulae X.sup.1--F.sup.1 or F.sup.1--X.sup.2. 3. The composition of matter of claim 1 of the formula F.sup.1-(L.sup.1).sub.c-P.sup.1. 4. The composition of matter of claim 1 of the formula F.sup.1-(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2. 5. The composition of matter of claim 1 wherein F.sup.1 is an IgG Fc domain. 6. The composition of matter of claim 1 wherein F.sup.1 is an IgG1 Fc domain. 7. The composition of matter of claim 1 wherein F.sup.1 comprises the sequence of SEQ ID NO: 2. 8. The composition of matter of claim 1 wherein P.sup.1 is a TPO-mimetic peptide sequence selected from Table 6. 9. The composition of matter of claim 8 wherein F.sup.1 comprises the sequence of SEQ ID NO: 2. 10. The composition of matter of claim 1 having a sequence selected from SEQ ID NOS: 6 and 12.

Details for Patent 7,189,827

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	NPLATE	romiplostim	For Injection	125268	08/22/2008		2018-10-23
Amgen, Inc.	NPLATE	romiplostim	For Injection	125268	10/17/2019		2018-10-23

International Patent Family for US Patent 7,189,827

Country	Patent Number	Estimated Expiration
Austria	380828
Australia	1232200
Australia	2001259432
Australia	2004200687
Australia	2004200690